DUBLIN, Dec. 20, 2016
/PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today
announced it has received approvals from the U.S. Food and Drug
Administration for Abbreviated New Drug Applications referencing
GlaxoSmithKline's Nicorette® White Ice Mint® Gum (nicotine
polacrilex gum 2 mg and 4 mg). These products will be packaged and
marketed as store brands or retailer 'own label' brands and provide
consumers with high-quality, value alternatives to Nicorette® White
Ice Mint® Gum.
Nicorette® White Ice Mint® Gum is used to help patients quit
smoking by reducing nicotine withdrawal symptoms. Annual sales for
the 12 months ending November 2016
were $79 million.
Perrigo's Executive Vice President & President, Consumer
Healthcare Americas, Jeff Needham commented that, "This
product approval reflects Perrigo's commitment to providing
customers and consumers with high quality value alternatives to
important OTC products. Perrigo's innovative OTC product offerings
are what drive value for our customers as they keep pace with
changing consumer preferences."
About Perrigo
Perrigo Company plc, a top five global over-the-counter ("OTC")
consumer goods and pharmaceutical company, offers patients and
customers high quality products at affordable prices. From its
beginnings in 1887 as a packager of generic home remedies, Perrigo,
headquartered in Ireland, has
grown to become the world's largest manufacturer of OTC products
and supplier of infant formulas for the store brand market. The
Company is also a leading provider of generic extended topical
prescription products and receives royalties from Multiple
Sclerosis drug Tysabri®. Perrigo provides Quality Affordable
Healthcare Products® across a wide variety of product categories
and geographies primarily in North
America, Europe, and
Australia, as well as other
markets, including Israel,
China and Latin America. Visit Perrigo online at
(http://www.perrigo.com).
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements." These statements relate to future events or the
Company's future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those
expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology
such as "may," "will," "could," "would," "should," "expect,"
"plan," "anticipate," "intend," "believe," "estimate," "predict,"
"potential" or the negative of those terms or other comparable
terminology. The Company has based these forward-looking statements
on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations,
assumptions, estimates and projections are reasonable, such
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company's control, including the timing, amount and cost of share
repurchases, future impairment charges, the ability to achieve its
guidance and the ability to execute and achieve the desired
benefits of announced initiatives. These and other important
factors, including those discussed under "Risk Factors" in the
Company's Form 10-KT for the six-month period ended December 31, 2015, as well as the Company's
subsequent filings with the SEC, may cause actual results,
performance or achievements to differ materially from those
expressed or implied by these forward-looking statements. The
forward-looking statements in this press release are made only as
of the date hereof, and unless otherwise required by applicable
securities laws, the Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/perrigo-announces-fda-approvals-for-the-store-brand-otc-equivalents-to-nicorette-white-ice-mint-gum-300381933.html
SOURCE Perrigo Company plc